Arrowhead Presents New P-II (ARCHES-2) Findings for Zodasiran at AHA 2023
Shots:
- In ARCHES-2 study (n=204) of zodasiran in patients with mixed dyslipidemia (fasting TGs: 150-499 mg/dL & either LDL-cholesterol >70 mg/dL or non-HDL-cholesterol >100 mg/dL), two doses of 50 mg, 100 mg, or 200 mg of zodasiran Q12W silenced ANGPTL3 expression & decreased atherogenic lipoproteins
- Zodasiran administration resulted in substantial reductions of ANGPTL3 up to -71% at wk 8, TGs up to 59% at wk 16, and LDL-C up to -32% at wk 16.
- ARO-ANG3 was associated with a relative reduction in liver fat fraction at wk24, with no AEs related to liver function test changes reported. ARO-ANG3 TEAEs are consistent with patient population and with associated underlying comorbidities
Ref: Arrowhead | Image: Arrowheadx
Related News:- Arrowhead Published New Findings from 2 P-II (SHASTA-2 & MUIR) studies for Plozasiran at AHA 2023
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.
